scholarly journals Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model

2007 ◽  
Vol 120 (8) ◽  
pp. 1803-1810 ◽  
Author(s):  
Sven A. Lang ◽  
Andreas Gaumann ◽  
Gudrun E. Koehl ◽  
Ulrike Seidel ◽  
Frauke Bataille ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Experimental Model ◽  
Mammalian Target Of Rapamycin ◽  
Target Of Rapamycin ◽  
Human Gastric Cancer

scholarly journals Phosphorylated Mammalian Target of Rapamycin p-mTOR Is a Favorable Prognostic Factor than mTOR in Gastric Cancer

PLoS ONE ◽  
2016 ◽  
Vol 11 (12) ◽  
pp. e0168085 ◽  
Author(s):  
Guo-dong Cao ◽  
Xing-yu Xu ◽  
Jia-wei Zhang ◽  
Bo Chen ◽  
Mao-ming Xiong
Keyword(s):  
Gastric Cancer ◽  
Prognostic Factor ◽  
Mammalian Target Of Rapamycin ◽  
Target Of Rapamycin ◽  
Favorable Prognostic Factor

scholarly journals Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer

BMC Cancer ◽  
2010 ◽  
Vol 10 (1) ◽  
Author(s):  
Da-zhi Xu ◽  
Qi-rong Geng ◽  
Ying Tian ◽  
Mu-yan Cai ◽  
Xin-juan Fang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Therapeutic Target ◽  
Mammalian Target Of Rapamycin ◽  
Target Of Rapamycin ◽  
Potential Therapeutic Target

scholarly journals Rictor Activates Cav 1 Through the Akt Signaling Pathway to Inhibit the Apoptosis of Gastric Cancer Cells

2021 ◽  
Vol 11 ◽  
Author(s):  
Rui-zhen Cao ◽  
Li Min ◽  
Si Liu ◽  
Ru-yue Tian ◽  
Hai-yan Jiang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Cells ◽  
Signaling Pathway ◽  
Cell Apoptosis ◽  
Mammalian Target Of Rapamycin ◽  
Akt Signaling ◽  
Target Of Rapamycin ◽  
Akt Signaling Pathway ◽  
Worse Prognosis

BackgroundRapamycin-insensitive companion of mammalian target of rapamycin (Rictor) protein is a core subunit of mammalian target of rapamycin complex 2, and is associated with cancer progression. However, the biological function of Rictor in cancer, particularly its clinical relevance in gastric cancer (GC) remains largely unknown.MethodsRictor expression and its association with clinicopathologic characteristics in GC were analyzed by immunohistochemistry. Effect of Rictor and Caveolin-1 (Cav 1) on GC cells apoptosis was evaluated via overexpression experiment in vitro. Mechanisms of Rictor and Cav 1 in GC were explored through overexpression and knockdown, by immunofluorescence and western blot analyses.ResultsRictor was upregulated in GC, and mainly located in the cytoplasm of cancer cells. Moreover, higher Rictor levels were associated with worse prognosis. Rictor could inhibit GC cell apoptosis and promote cell growth in vitro. The results of immunofluorescence revealed that Cav 1 localized in GC cell membrane but did not co-localize with Rictor. Further, Rictor regulated apoptosis-related proteins, long non-coding RNAs and also activated cellular signaling, thereby positively regulating Cav 1 expression. This effect was attenuated by the Akt inhibitor ly294002. Cav 1 did not significantly affect the ability of Rictor to inhibit tumor cell apoptosis.ConclusionsRictor is upregulated in GC and associated with worse prognosis. It inhibits tumor apoptosis and activates Cav 1 through the Akt signaling pathway to inhibit the apoptosis of GC cells. Rictor is, therefore, a promising prognostic biomarker and possible therapeutic target in GC patients.

scholarly journals Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-Fluorouracil inPIK3CAmutant gastric cancer cells

2012 ◽  
Vol 13 (1) ◽  
pp. 34-42 ◽  
Author(s):  
Bhaskar Bhattacharya ◽  
Mohamed Akram ◽  
Indirikumar Balasubramanian ◽  
Kimberley K.Y. Tam ◽  
King X. Koh ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Cells ◽  
Mammalian Target Of Rapamycin ◽  
Target Of Rapamycin ◽  
Gastric Cancer Cells ◽  
Phosphoinositide 3 Kinase
Sign in / Sign up

Export Citation Format

Share Document